Impressive Financial Growth for Pharming Group in Q3 2025
Company Reports Significant Revenue Upsurge
Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) has announced its stellar financial performances for the third quarter of 2025, showcasing remarkable achievements in revenue, operational profit, and cash flow. The Company’s total revenues soared by 30% to reach US$97.3 million compared to the same period in 2024, driven largely by strong sales of their innovative drug RUCONEST® and the growth of Joenja® (leniolisib).
Key Highlights of Q3 2025
Notably, the revenue generated from RUCONEST® rose by 29% to US$82.2 million, marking continued momentum in the treatment of acute Hereditary Angioedema (HAE) attacks. Joenja®, aimed at addressing APDS, also experienced significant growth, with revenues climbing by 35% to US$15.1 million. This increase reflects the successful expansion in the patient base and the effectiveness of their therapies, strengthening Pharming's market position substantially.
Operating Profit and Cash Flow Reported
Pharming reported an operating profit increase of an impressive 285%, which amounted to US$15.8 million, compared to US$4.1 million one year earlier. With US$32.0 million generated from operations during the quarter, Pharming further extended its year-to-date cash flows to US$44.0 million, attesting to the Company's enhanced operational efficiency.
Future Outlook and Growth Strategies
In light of the positive performance, Pharming has raised its revenue guidance for the year to between US$365 - US$375 million, a proactive adjustment from the previous estimate of US$335 - US$350 million. The strategic planning focuses on maximizing market share for RUCONEST® and further broadening access to Joenja®, particularly in the pediatric segment with a supplemental New Drug Application (sNDA) pending for the treatment of younger patients with APDS.
Pipeline Developments and Organizational Changes
The Company’s pipeline also shows promise, with advancements towards new indications for leniolisib and ongoing efforts to explore potential clinical applications in mitochondrial diseases with their product KL1333. Furthermore, the recent appointment of Leverne Marsh as Chief Commercial Officer reflects a directed effort towards strengthening the Company’s operational framework.
Financial Position Enhancement
As of September 30, 2025, Pharming continued their financial resilience, with total assets recorded at US$473.8 million. Their current live insights and performance indicate a robust trajectory and adaptability to market conditions.
Frequently Asked Questions
1. What are the key highlights of Pharming’s Q3 2025 financial results?
Pharming reported a 30% increase in revenues to US$97.3 million. RUCONEST® sales rose by 29% to US$82.2 million, and Joenja® by 35% to US$15.1 million.
2. How has Pharming improved its operating profit?
The Company’s operating profit increased by 285% to US$15.8 million compared to Q3 2024, attributing its growth to heightened revenues and operational efficiencies.
3. What is the updated revenue guidance for Pharming Group?
Pharming has revised its revenue outlook for 2025 to between US$365 million and US$375 million, up from prior estimates of US$335 million to US$350 million.
4. Who has been appointed as the new Chief Commercial Officer of Pharming?
Leverne Marsh has been appointed as the Chief Commercial Officer, effective January 1, 2026, bringing extensive experience to empower Pharming’s strategy.
5. What are Pharming’s future plans regarding its product pipeline?
Pharming is focused on advancing its pipeline for leniolisib and KL1333, while also preparing for pediatric label expansion and increased regulatory approvals.
